Explore Our Featured Blogs

Rosacea recurs because most treatments target symptoms, not the cascade driving them. Learn how the inflammation-first approach delivers durable outcomes across all skin types.

For 30 years, Aerolase has built laser technology around a single principle: safe, effective treatment for all Fitzpatrick skin types. Here's the story behind the science.

Aerolase founder Pavel Efremkin shares the 30-year journey behind pioneering 650-microsecond pulse technology, transforming dermatological lasers with pain-free treatments safe for all skin types.

300-microsecond Er:YAG laser technology makes ablative resurfacing safe for Fitzpatrick IV-VI patients. Learn how the Aerolase Era eliminates PIH risks.

Learn how to integrate laser intimate wellness treatments into your OBGYN or aesthetic practice. Practical guide for starting patient conversations, choosing services, and building a successful program.

Aerolase Neo Elite wins Best Acne Device and Era Elite named finalist for Best Laser Skin Resurfacing in 2025 MedEsthetics Readers' Choice Awards.

Discover how plastic surgeons use Aerolase Neo and Era lasers for aesthetic surgery, acne treatment, and scar revision. Clinical protocols, case studies, and practice integration strategies from Dr. James Newman.

Razor bumps (PFB) affect 83% of black men. Learn the treatment protocol, patient demographics, and revenue potential most practices are missing.

Why do medspas lose 67% of potential revenue? Silent leaks. Discover how Aerolase laser technology solves retention, conversion, and predictability issues.

Compare regenerative vs. destructive laser treatments. Neo Elite 1064nm and Era 2940nm microsecond lasers stimulate collagen without tissue damage. Clinical results included.

How Aerolase Neo (1064 nm) & Era (2940 nm) help plastic surgeons reduce bruising, improve scars, clear acne, and boost ROI—with peer-reviewed data.

Survey results reveal demand for intimate rejuvenation. See how Aerolase lasers provide clinical solutions for feminine wellness.

Peer-reviewed data on 650-microsecond pulse duration for inflammatory acne. FDA-cleared for all Fitzpatrick types with 87% lesion reduction at 90 days.

New research confirms inflammation triggers acne before visible lesions form. Updated clinical protocols for targeting subclinical inflammation in all skin types.

Men now account for 15% of aesthetic procedures. Learn proven marketing strategies and treatment protocols that convert male consultations into loyal patients.

Dr. Jean-Marc Adda shares his clinical experience using the Aerolase Neo Elite to treat acne, melasma, and complex skin conditions across all skin types.

43% of consumers pay more for evidence-backed treatments. Dual-wavelength protocol for enhancing surgical outcomes, reducing complications, and boosting patient satisfaction.

Discover how Aerolase Neo & Era lasers deliver personalized, drug-free acne and skin rejuvenation treatments for all skin types—safely and effectively.

Before you revamp your treatment offerings or sign on the dotted line, ask these five critical questions—and see how Aerolase® not only meets but exceeds expectations in every category.

If you are a follower of groundbreaking skin treatments, you might have seen the use of Aerolase blowing up across the U.S., Canada, and Australia, and now this advanced skin treatment is available in Newmarket, offering a new age of laser technology.

We sat down with Sean Johnson, VP of Marketing for Aerolase, to explore the innovations, milestones, and bold rebranding set to reshape light-based skin treatments worldwide.

Clinical data on dual-wavelength rejuvenation protocols. How combining 1064nm and 2940nm lasers improves outcomes for aging skin with minimal downtime.

Increase treatment revenue 40% by pairing laser and injectables. Proven consultation scripts, treatment sequencing, and package pricing strategies that work.

Men's skincare market hits $28B by 2029. Men spend $732 per visit vs. $524 for women. How to build a profitable men's aesthetic service line in your practice.